First-in-class biopharmaceutical for treating osteoarthritis
Levicept is developing a biological fusion protein, p75NTR-Fc, comprising the endogenous human neurotrophin receptor and an immunoglobulin Fc fragment, for treating chronic pain in patients with osteoarthritis.
Advent invested in the Series A in 2014.